Eloxx Pharmaceuticals, Inc. IPO Filing Research

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS in the pre-IPO sequence.

Common Stock · Exchange Nasdaq · Ticker ELOX · Pre-funded warrants to purchase common stock at $0.01 exercise price · Use of proceeds Working capital, research and development, and other general corporate purposes · Underwriters Leerink Partners, Guggenheim Securities

2026-05-07 · 0001193125-26-212324

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after 424B5.

2026-03-20 · 0001193125-26-116406

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $5.26 · 305,590 shares · Gross proceeds $1,999,925

Common Stock · Exchange NASDAQ · Ticker ELOX · Pre-Funded Warrants to purchase 75,000 shares at $0.001 exercise price · Use of proceeds for general corporate purposes · Flags warrants · Underwriters H. C. Wainwright & Co., LLC

2023-09-20 · 0001104659-23-102237

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $4,200,000

Common Stock · Exchange Nasdaq Capital Market · Ticker ELOX · Underwriters Oppenheimer & Co. Inc.

2023-08-11 · 0001104659-23-090478

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $6,500,000

Common Stock · Exchange Nasdaq Capital Market · Ticker ELOX · Underwriters Oppenheimer & Co. Inc.

2023-05-24 · 0001104659-23-063905

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $12,996,795

Common Stock · Exchange Nasdaq Global Market · Ticker ELOX · Use of proceeds Working capital · Underwriters SVB Securities LLC

2022-05-06 · 0001104659-22-057042

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $50,000,000

Common Stock · Exchange Nasdaq Global Market · Ticker ELOX · Underwriters SVB Leerink LLC

2021-09-30 · 0001104659-21-121031

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2021-08-30 · 9999999995-21-003359

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $1.35 · 33,333,334 shares · Gross proceeds $45,000,001

Common · Exchange Nasdaq Global Market · Ticker ELOX · Over-allotment 5,000,000 · Use of proceeds for general corporate purposes · Underwriters B. Riley Securities

2021-05-17 · 0001104659-21-068042

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Common · Exchange Nasdaq Global Market · Ticker ELOX · Underwriters B. Riley Securities

2021-05-13 · 0001104659-21-065986

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $9.00 · 3,333,334 shares · Gross proceeds $30,000,006

Common Stock · Exchange Nasdaq Global Market · Ticker ELOX · Over-allotment 500,000 · Use of proceeds Proceeds will be used for general corporate purposes. · Underwriters Citigroup Global Markets Inc., Piper Jaffray & Co.

2019-06-20 · 0001144204-19-031715

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Global Market · Ticker ELOX · Underwriters Citigroup Global Markets Inc., Piper Jaffray & Co.

2019-06-19 · 0001144204-19-031477

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2018-11-26 · 9999999995-18-002971

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Global Market · Ticker ELOX · Use of proceeds general corporate purposes · Underwriters Citigroup Global Markets Inc., Cantor Fitzgerald & Co.

Eloxx Pharmaceuticals, Inc. filed a prospectus supplement (424B5) on November 16, 2018, relating to the offer and sale of up to $50 million in common stock through Sales Agents (Citigroup Global Markets Inc. and Cantor Fitzgerald & Co.). This follows a prior filing in April 2018, which detailed a specific share offering. The current supplement outlines an equity distribution agreement allowing sales at the market, with commissions up to 3% of gross sales. The company’s common stock is listed on Nasdaq under 'ELOX.'

2018-11-16 · 0001144204-18-060508

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows CERT and confirms the priced prospectus.

Price $9.75 · 5,130,000 shares · Gross proceeds $50,017,500

Common Stock · Exchange NASDAQ · Ticker ELOX · Over-allotment 769,500 · Use of proceeds to fund clinical development of ELX-02 and for working capital and other general corporate purposes · Underwriters Citigroup, Piper Jaffray, Canaccord Genuity

Eloxx Pharmaceuticals, Inc. is offering 5,130,000 shares of common stock at $9.75 per share, with net proceeds estimated at $46.3 million. The offering includes an underwriter option to purchase an additional 769,500 shares. The company focuses on developing therapies for rare genetic diseases using genetic read-through technology, with clinical programs targeting cystic fibrosis and cystinosis. The filing reflects a merger with Sevion Therapeutics, Inc., resulting in a name change and restructuring.

2018-04-26 · 0001193125-18-132800

CERT inactive

CERT

Pre-IPO filing captured from the SEC submission timeline.

Follows 8-A12B in the pre-IPO sequence.

The current filing appears to be an incomplete or corrupted document, potentially a test or placeholder, as it contains non-readable PDF data. The previous 8-A12B filing detailed Eloxx Pharmaceuticals' registration of common stock for listing on Nasdaq, including corporate information and securities description references.

2018-04-25 · 0001354457-18-000115

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $10.70 · 5,000,000 shares · Gross proceeds $53,500,000

Common Stock · Exchange Nasdaq · Ticker ELOX · Over-allotment 750,000 · Use of proceeds to fund part of the continued clinical development of ELX-02 · Underwriters Citigroup, Piper Jaffray, Canaccord Genuity

Eloxx Pharmaceuticals, Inc. is offering 5,000,000 shares of common stock, with an expected listing on Nasdaq Global Market under the symbol 'ELOX' following the offering. The company plans to use net proceeds of approximately $49.6 million for clinical development of ELX-02, a drug candidate for rare genetic diseases, and for general corporate purposes. The filing includes details about the merger with Sevion Therapeutics, Inc., which led to the company's name change and restructuring. Risk factors include dependence on ELX-02's clinical success, regulatory challenges, and potential disputes with licensors.

2018-04-24 · 0001193125-18-128991

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows 424B5 and registers the class of securities for exchange listing.

Eloxx Pharmaceuticals, Inc. filed Form 8-A12B to register its common stock for listing on The Nasdaq Stock Market, referencing a previously filed S-3 registration statement (333-224207). This follows a prospectus supplement (424B5) detailing a $5M common stock offering, underwritten by Citigroup, Piper Jaffray, and others, with plans to list under the symbol 'ELOX' after pricing. The company focuses on developing therapies for rare genetic diseases using genetic read-through technology.

2018-04-24 · 0001193125-18-129019

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows RW and marks the registration effective.

Eloxx Pharmaceuticals, Inc. received effectiveness for its S-3 registration statement on April 20, 2018, replacing a prior S-1 registration (File No. 333-207375) that was withdrawn in 2016. The company previously operated as Sevion Therapeutics, Inc. and withdrew its S-1 filing due to unspecified reasons, with no securities sold under the withdrawn registration.

2018-04-20 · 9999999995-18-000879

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows S-1 and ends the active registration process.

Sevion Therapeutics, Inc. requested the withdrawal of its Form S-1 registration statement, effective immediately. The company confirmed no securities were sold under the registration, and fees paid to the SEC will be credited for future use. The withdrawal aligns with Rule 477, citing public interest and investor protection.

2016-10-31 · 0001144204-16-130558

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

Price $0.60 · 9,842,992 shares · Gross proceeds $0.00

half of one share · Exchange OTCQB · Ticker SVON · Units consisting of common stock or Series C Convertible Preferred Stock and a warrant to purchase half a share of common stock · Warrants to purchase 0.5 shares of common stock at $1.50 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be used for general corporate purposes and working capital · Flags warrants · Underwriters selling stockholders

The current S-1 filing by Sevion Therapeutics, Inc. relates to the resale of up to 9,842,992 shares of common stock by selling stockholders, including 200% of shares issuable upon exercise of warrants from a 2015 private placement. The company, a development-stage biotechnology firm, focuses on innovative therapeutics for cancer and immunological diseases. The offering follows a private placement that raised approximately $5.98 million, with proceeds intended for research and development. The filing includes a registration rights agreement for warrant holders and details the plan for share distribution.

2015-10-09 · 0001144204-15-058943

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

1,800,000 shares

Common Stock · Ticker SEN · Units consisting of common stock and warrants · Series A, B, and C Warrants to purchase common stock · Flags units, warrants

The filing is a prospectus supplement (No. 2) for Senesco Technologies, Inc.'s offering of 180,000 units containing common stock, warrants, and underlying shares. It incorporates a quarterly report (10-Q) for the fiscal quarter ended March 31, 2014, updating financial disclosures and supplementing the prospectus with revised financial data and risk factors.

2014-05-09 · 0001144204-14-029023

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B4 and confirms the priced prospectus.

1,800,000 shares

common stock, warrants · common stock, warrants · Series A, B, and C warrants to purchase 1,800,000 shares each · Flags units, warrants

The current filing is a prospectus supplement (Form 424B3) for Senesco Technologies, Inc., incorporating a quarterly report (10-Q) for the period ended December 31, 2013. It updates financial disclosures and reiterates risks associated with the offering, including lack of revenue, regulatory compliance, and market volatility. The supplement supersedes prior prospectus information and emphasizes the high-risk nature of investing in the company's securities.

2014-02-14 · 0001144204-14-010007

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

1,800,000 shares

Common Stock · Exchange OTCQB · Ticker SENES · 180,000 units consisting of 1,800,000 shares of common stock and warrants · Series A, B, C Warrants to purchase 1,800,000 shares each · Use of proceeds Not specified in filing · Flags units, warrants

This filing serves as a prospectus supplement for Senesco Technologies, Inc.'s offering of 180,000 units containing 1.8 million shares of common stock and related warrants. It incorporates by reference the company's quarterly report on Form 10-Q for the fiscal quarter ended December 31, 2013, and highlights risks associated with investing in development-stage securities.

2014-02-14 · 0001144204-14-010053

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $30.00 · 1,800,000 shares · Gross proceeds $5,400,000

Common Stock with Warrants · Exchange OTCQB · Ticker SNTI · 10 Shares of Common Stock, Series A Warrants to purchase 10 Shares, Series B Warrants to purchase 10 Shares, and Series C Warrants to purchase 10 Shares · Series A Warrants (exercise price $3, exercisable 6 months), Series B Warrants (exercise price $4, exercisable 6 months), Series C Warrants (exercise price $4, exercisable 3 years)

Senesco Technologies, Inc. is offering 180,000 units, each consisting of 10 shares of common stock and warrants (Series A, B, C) exercisable at $3-$4 per share. The offering aims to raise $5.4M in gross proceeds, with proceeds allocated to product commercialization, development, and working capital. The company, a development-stage firm focused on therapeutic and agricultural technologies, highlights risks including regulatory compliance, intellectual property protection, and market volatility. Its common stock trades on the OTCQB under SNTI.

2013-12-12 · 0001144204-13-066846

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $49.80 · 903,620 shares · Gross proceeds $4,500,000

Common Stock · Exchange OTCQB · Ticker SNTI · Each unit contains 10 shares of common stock and Series A, B, C warrants · Warrants exercisable at unspecified prices (blanks in filing) with varying expiration terms · Use of proceeds for general corporate purposes and to fund operations · Flags units, warrants

Senesco Technologies, Inc. is offering 90,362 units, each consisting of 10 shares of common stock and warrants, with gross proceeds of $4.5 million. The company is a development-stage biotechnology firm focused on therapeutic research for diseases like multiple myeloma and agricultural technology licensing. The offering includes Series A, B, and C warrants with varying exercise prices and terms. The filing reflects a reverse stock split and adjustments to share counts and pricing.

2013-12-11 · 0001144204-13-066729

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Senesco Technologies, Inc. is a development-stage company focused on therapeutic research, including a candidate (SNS01-T) for multiple myeloma and other cancers, with orphan drug designation. The filing outlines an offering of 90,362 units containing common stock and warrants, with proceeds intended for clinical trials, research, and general operations. The company has no significant revenue and relies on external research partnerships and agricultural licensing agreements.

2013-12-11 · 9999999995-13-003519

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $49.80 · 903,620 shares · Gross proceeds $4,500,000

Common Stock · Exchange OTCQB · Ticker SNTI · Each unit contains 10 shares of common stock and warrants · Series A (6-month exercise), Series B (6-month exercise), Series C (3-year exercise) · Use of proceeds To fund operations and research and development · Flags units, warrants

Senesco Technologies, Inc. is offering 90,362 units, each consisting of ten shares of common stock and Series A, B, and C warrants. The offering aims to raise $4.5 million, with proceeds intended for product commercialization, pipeline development, and working capital. The company, a development-stage biotech firm, focuses on therapeutic candidates for multiple myeloma and agricultural technology licensing. Its common stock trades on the OTCQB under SNTI.

2013-12-06 · 0001144204-13-066138

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Gross proceeds $10,000,000

Common Stock · Exchange OTCQB · Ticker SNTI · Each unit consisting of shares of our common stock · Use of proceeds General corporate purposes · Flags units

Senesco Technologies, Inc. is a development-stage company focused on therapeutic research and agricultural technology licensing. The S-1/A filing amends the original S-1 to register an offering of units consisting of common stock, with gross proceeds of $10M. The company is advancing a therapeutic candidate, SNS01-T, for multiple myeloma and other cancers, while also pursuing agricultural licensing agreements. The filing includes a reverse stock split (1-for-100) and updated financial disclosures.

2013-11-27 · 0001144204-13-064464

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B4 in the pre-IPO sequence.

Gross proceeds $10,000,000

Units, each unit consisting of shares of common stock · Exchange OTCQB · Ticker SNTI · Each unit consists of shares of common stock · Use of proceeds working capital and general corporate purposes · Flags units

Senesco Technologies, Inc. is offering units consisting of shares of common stock in a $10 million public offering, aiming to advance its therapeutic research and agricultural licensing initiatives. The company, a development-stage entity, focuses on developing SNS01-T for cancer treatments and holds orphan drug designations. Previous filings detailed a smaller $1.725 million offering, with the current S-1 expanding on financial details and risk factors.

2013-10-17 · 0001144204-13-055661

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $5.00 · 69,000,000 shares · Gross proceeds $1,725,000

Common Stock · Exchange OTCQB · Ticker SNTI · Each unit consisting of 200 shares of common stock

Senesco Technologies, Inc. is offering 345,000 units, each consisting of 200 shares of common stock, at $5.00 per unit, generating $1.725 million in gross proceeds. The offering follows a previous S-1 registration statement. The company, a biotechnology firm, focuses on therapeutic research for diseases like multiple myeloma and has agricultural licensing agreements. Proceeds will fund product commercialization, development, and working capital. Its common stock trades on the OTCQB under SNTI.

2013-10-01 · 0001144204-13-053351

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The filing confirms the effectiveness of Senesco Technologies, Inc.'s S-1 registration statement on September 30, 2013, allowing the company to proceed with its securities offering. The offering involves 250,000 units, each consisting of 200 shares of common stock, with gross proceeds estimated at $2 million before expenses. The company, a development-stage biotechnology firm, focuses on therapeutic research for diseases like multiple myeloma and has agricultural licensing agreements for crop technologies.

2013-09-30 · 9999999995-13-002825

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $2,000,000 · 250,000 shares

Common Stock · Exchange OTCQB · Ticker SNTI · Each unit consists of 200 shares of common stock · Use of proceeds Proceeds will be used for general corporate purposes · Flags units, self_underwritten · Underwriters self-underwritten

Senesco Technologies, Inc. is a development-stage biotechnology company focused on developing therapeutic candidates for cancer treatment, including SNS01-T for multiple myeloma and other cancers, and has agricultural licensing agreements. The current S-1/A filing details an offering of 250,000 units (200 shares each) to raise $2 million, with net proceeds estimated at $1.78 million. The company has no revenue, relies on third-party research, and faces significant regulatory and financial risks.

2013-09-27 · 0001144204-13-052767

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

62,500,000 shares · Gross proceeds $2,500,000

common stock included in the Units · Exchange OTCQB · Ticker SNTI · each unit consisting of two hundred shares of common stock · Use of proceeds working capital · Flags units

Senesco Technologies, Inc. is a development-stage biotechnology company focused on therapeutic research for human diseases and agricultural technology licensing. The company is offering 312,500 units, each consisting of 200 shares of common stock, to raise approximately $2.5M. The offering includes a Phase 1b/2a clinical trial for SNS01-T, a therapeutic candidate for multiple myeloma, and orphan drug designation from the FDA. The company also holds nine agricultural licensing agreements for crop applications. Senesco has not generated significant revenue and relies on external financing for operations.

2013-09-25 · 0001144204-13-052398

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Units consisting of five shares of common stock and a warrant to purchase five shares of common stock · Exchange OTCQB · Ticker SNTI · Units consisting of five shares of common stock and a warrant to purchase five shares of common stock · Warrants exercisable at $0.05 per share, expiring on the second anniversary of the issuance date · Use of proceeds general corporate purposes

Senesco Technologies, Inc. is conducting an IPO offering units consisting of five shares of common stock and a warrant to purchase five shares. The offering aims to raise $15 million, with proceeds用于 product commercialization, development, and working capital. The company, a development-stage biotech firm, focuses on therapeutic candidates for cancer and agricultural technologies. Its common stock trades on the OTCQB under SNTI, and the filing includes detailed risk factors related to regulatory compliance, intellectual property, and market volatility.

2013-09-20 · 0001144204-13-051820

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B5 in the pre-IPO sequence.

Common Shares, $0.01 par value per share · Ticker SNTI · Underwriters Chardan Capital Markets, Dawson James Securities

Senesco Technologies, Inc. is a development-stage biotechnology company focused on therapeutic research, particularly for multiple myeloma, with a clinical candidate SNS01-T granted orphan drug status by the FDA. The company is offering common shares to fund product commercialization, research, and general operations, with plans to list on a national exchange. It also holds agricultural licensing agreements for biotech applications.

2013-07-17 · 0001144204-13-039968

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.03 · 41,833,335 shares · Gross proceeds $1,255,000

Common · Exchange OTCQB · Ticker SNTI · Use of proceeds for general corporate purposes which may include research and development, sales and marketing, general administrative expenses, working capital, capital expenditures and future acquisitions · Underwriters Chardan Capital Markets, LLC

Senesco Technologies, Inc. is offering 41,833,335 shares of common stock at $0.03 per share, with net proceeds estimated at $1.13 million. The offering is part of a series of SEC-registered offerings, with proceeds intended for general corporate purposes including R&D, sales, and capital expenditures. The company, a development-stage biotech firm, focuses on gene therapy research and agricultural licensing. The placement agent is Chardan Capital Markets, LLC.

2013-05-09 · 0001144204-13-027314

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.10 · 30,000,000 shares

Common Stock · Exchange OTCQB · Ticker SNTI · 30,000,000 Units consisting of 30,000,000 Shares of Common Stock and Warrants to Purchase 30,000,000 Shares of Common Stock · Warrants to purchase 30,000,000 shares of common stock at $0.12 per share, exercisable after 1 year and 1 day for 5 years · Use of proceeds Use of proceeds includes investor relations and general corporate purposes such as research and development, sales, and marketing · Flags units, warrants

Senesco Technologies, Inc. is offering 30,000,000 units consisting of 30,000,000 shares of common stock and warrants to purchase 30,000,000 shares. The offering price is $0.10 per unit, with net proceeds estimated at $2.9M. The company is a development-stage biotech firm focused on gene therapy for multiple myeloma and other cancers, with agricultural licensing agreements. Proceeds will fund investor relations and general corporate purposes, including R&D and acquisitions.

2013-01-07 · 0001144204-13-000844

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.26 · 3,846,154 shares · Gross proceeds $999,999

Shares of Common Stock · Exchange NYSE Amex · Ticker SNT · One share of common stock and a warrant to purchase one-half of a share · Warrants exercisable at $0.286 per share, 6 months after issuance, 5-year term · Use of proceeds Use of proceeds will be for general corporate purposes including research and development, working capital, and potential acquisitions

Senesco Technologies, Inc. is offering 3,846,154 shares of common stock and warrants to purchase 1,923,077 shares, with proceeds intended for general corporate purposes including R&D, sales, and debt repayment. The offering follows prior filings and highlights risks related to clinical trials, regulatory approval, and market volatility.

2012-03-02 · 0001144204-12-012526

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows 424B5 and supplements the active offering with updated prospectus details.

Price $0.26 · Range $0.23 to $0.26 · Gross proceeds $3,000,000

common stock, par value $0.01 per share and warrants · warrants exercisable at $0.286, 6-month hold, 5-year term · Use of proceeds research and development spending and general corporate purposes · Flags best_efforts, warrants

The current FWP outlines a private placement offering by Senesco Technologies, Inc. for up to $3 million in common stock and warrants, targeting accredited investors. The offering includes a minimum investment of $25,000, with shares priced at $0.26 each and warrants exercisable at $0.286. The previous 424B5 filing detailed a $5.5 million at-the-market offering via McNicoll Lewis & Vlak, focusing on common stock with a sales agent structure. The FWP emphasizes private placement terms, including non-shorting clauses and registration under Form S-3.

2012-01-09 · 0001144204-12-001231

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows FWP and confirms the priced prospectus.

Price $0.26 · 8,653,846 shares · Gross proceeds $2,250,000

Common · Exchange NYSE Amex · Ticker SNT · 1 share of common stock and a warrant to purchase 0.5 shares of common stock · Warrants to purchase 3,750,000 shares of common stock exercisable at $0.286 per share · Use of proceeds general corporate purposes including research and development, sales and marketing, and working capital · Flags units, warrants

Senesco Technologies, Inc. is offering 8,653,846 shares of common stock and warrants to purchase 3,750,000 shares, with each share accompanied by a warrant for half a share. The offering price is $0.26 per unit, with warrants exercisable at $0.286 per share after six months. Proceeds will fund research, development, and general corporate purposes. The company's stock is listed on NYSE Amex, with a recent price of $0.26 per share.

2012-01-09 · 0001144204-12-001378

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $5,500,000

Common Stock · Exchange NYSE Amex · Ticker SNT · Underwriters McNicoll Lewis & Vlak

Senesco Technologies, Inc. filed a 424B5 prospectus supplement to register up to $5.5 million in common stock offerings through McNicoll Lewis & Vlak as an agent. The offering allows for at-the-market sales, with proceeds intended for general corporate purposes. The filing updates details from the prior S-3 shelf registration, including the sales agreement terms, commission structure, and anti-dilution provisions tied to existing preferred stock conversions.

2010-12-22 · 0001144204-10-067925

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

The filing represents a Notice of Effectiveness for Senesco Technologies, Inc.'s Form S-3 registration statement, allowing the resale of 65,435,938 shares of common stock. The shares are issuable from prior private placements and warrants, with no direct proceeds to the company from resale but potential proceeds from warrant exercises. The prospectus outlines risks associated with the company's early-stage biotechnology research and clinical trials.

2010-11-09 · 9999999995-10-003182

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

65,435,938 shares

common · Exchange NYSE Amex · Ticker SNT · 33,257,813 common stock purchase warrants issued in April 2010 · Selling stockholders only · Use of proceeds Proceeds from exercise of April 2010 warrants

The filing is a prospectus for Senesco Technologies, Inc. detailing the resale of 65,435,938 shares of common stock by selling securityholders. These shares include 32,178,125 from the conversion of Series A preferred stock and 33,257,813 from warrant exercises. The company will not receive proceeds from the resale but may benefit from cash exercises of warrants. The shares are offered through over-the-counter markets, negotiated transactions, or other methods. The company's stock is listed on NYSE Amex under 'SNT', with a recent closing price of $0.51 as of June 16, 2010.

2010-06-24 · 0001144204-10-034765

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows RW and marks the registration effective.

The filing confirms the effectiveness of Senesco Technologies, Inc.'s Form S-3 registration statement on June 23, 2010, following a prior request to withdraw the same registration in 2008. The 2008 withdrawal was due to modified transaction terms eliminating the need for share registration, with no securities sold under the original filing.

2010-06-23 · 9999999995-10-001908

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

First tracked pre-IPO filing for this issuer.

Senesco Technologies, Inc. requests the withdrawal of its Form S-3 registration statement for 891,667 shares of common stock due to modified transaction terms that eliminate the need for share registration. The registration was never effective, and no securities were sold. The company also seeks fee credits under Rule 457(p).

2008-03-19 · 0001104659-08-018472

Eloxx Pharmaceuticals, Inc.

Filing Timeline

10 comparable deals

Recent News